Ad
Search
Generic filters
Filter by content type
Taxonomy terms

CEMI – Chembio Diagnostics Inc

🔒

Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month

Ad
N/A

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Total Analysts: 0

Company Profile

Chembio Diagnostics, Inc. develops and commercializes point-of-care diagnostic tests used for the rapid detection and diagnosis of infectious diseases, including sexually transmitted disease, insect vector and tropical disease, COVID-19, and other viral and bacterial infections, enabling expedited treatment. Its product portfolio is based upon its DPP technology, a diagnostic platform that provides results in 15 to 20 minutes using fingertip blood, nasal swabs, and other sample types. The DPP technology platform addresses the rapid diagnostic test market, which includes infectious diseases such as sexually transmitted infections (STIs) and human immunodeficiency virus (HIV), gastroenterology, and women’s health. Its products include COVID-19 Antibody Test System, COVID-19 Antigen Test System, COVID-19 and Influenza Respiratory Antigen Panel Test System and HIV-Syphilis Diagnostic Test Systems, among others. It is also targeting lateral flow test solutions for infectious diseases.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses